Xenetic Biosciences, Inc. (XBIO) income statement
XBIONasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 12/3066% below fair value
$1.53−0.08 (-4.97%)
Close on Nov 18, 2026Market cap $3.59MP/E –Yield –
Xenetic Biosciences, Inc. income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, TTM
- Gross margin
- –
- Operating margin
- -81.0%
- Net margin
- -75.9%
- Return on equity, FY2025
- -40.0%
Financial strength
- Current ratio
- 7.43
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 723.1%
Valuation
- P/E ratio
- –
- Price to sales
- 1.10
- Price to book
- 0.59
- Dividend yield
- –
See a number that looks wrong?